With limited visits, it's time for medical representatives to return to "nature."

2020 is an unforgettable year for pharmaceutical representatives. At the beginning of, most hospitals temporarily closed many clinics because of the outbreak, allowing patients to choose online consultations as much as possible, reducing the chances of going to the hospital.this means an unexpected and unavoidable decline in the first quarter of the first quarter or even in the first half of the year for specialist prescription drugs unrelated to the outbreak.and in the second half of the year, a number of medical reform measures came into effect, drug companies limited marketing activities, and new policies to the medical representatives of the visit activities of restrictions.July 24, the National Health and Care Commission Office issued "on the issuance of the 2020 medical industry style construction special action program notice" clearly stated that from July this year to the end of the year, will focus on the treatment of medical personnel to collect kickbacks, pharmaceutical companies illegal marketing behavior.mainly investigates and punishes medical institutions and practitioners for obtaining improper benefits by using their practice to obtain improper benefits and collecting kickbacks, as well as the acts of commercial negotiations in the production, operation or distribution of pharmaceutical products or distribution personnel in medical institutions' outpatient clinics, inpatient departments, pharmacies and other areas.industry generally believes that the latter means that medical representatives will be subject to greater restrictions on access to hospitals to visit doctors.in fact, with marketing compliance and pharmaceutical anti-commercial bribery has become the focus of attention in recent years, many hospitals have issued regulations, in strict restrictions on the activities of medical representatives.as early as 2018, Shanghai Fudan University affiliated Huashan Hospital has launched the pharmaceutical company representative appointment filing system, Shanghai Hongkou District is a second-level general hospital Jiangwan Hospital notice that the varieties signed a three-copy "clean self-discipline commitment" with the hospital before May 31, and at the same time provide "one inch, two inch photo each one and a copy of the document" for the medical representative for the record.last year, Sichuan Provincial People's Hospital issued a text to rectify the medical representative "full hospital fly", a number of measures to limit the activities of representatives.include the continuous elimination of the "promoted" space, the implementation of the supplier centralized recommendation day system, the standardization of clinical medical and technical departments to receive pharmaceutical enterprises, rectify the standard administrative building office order, strict inspection and supervision to ensure the implementation of the work.in addition to the above places, at present, Guangxi, Shanghai, Tianjin, Beijing and other countries have also been issued on the medical representatives of the regulatory documents.Although the requirements of the policy provisions vary from place to place, they are clearly an end in itself.in fact, in recent years, with the gradual implementation and promotion of the volume of procurement in the pilot cities, the registration of medical representatives in major provinces and cities and hospitals have become more popular, with gold sales space is being greatly compressed, the pharmaceutical industry anti-corruption red line has been repeatedly refreshed., such as Shandong, Fujian, Hunan, Zhejiang and other provinces and cities of the regulatory authorities have in the annual public affairs open work, the medical representative registration of the information disclosure work as the focus.overall, the restriction of face-to-face visits by pharmaceutical representatives and marketing compliance are an unalterable trend.but it is worth noting that the continuous changes in the industry, in the process of promoting the return of pharmaceutical representatives to academic promotion, the delegates to reshuffle at the same time, but also brought them new opportunities and challenges., such as in recent years, the country vigorously develop primary health care, there are many pharmaceutical companies will be business down to primary health care or four-line five-line cities, and is forming a grass-roots sales force, open up a broad grass-roots market.in addition to Pfizer, AstraZeneca, Bayer, Mercado, GlaxoSmithKline and other major foreign pharmaceutical companies, are vigorously recruiting grass-roots pharmaceutical representatives, China Resources Shuanghe, Zhejiang Jingxin, Yunnan White Medicine and many other well-known domestic pharmaceutical companies are also actively layout.this case, the cost of a traditional one-on-one visit has increased dramatically.at this time, medical representatives can go to multi-channel skills training, in order to meet the future promotion requirements.it is worth noting that QQ, telephone and other visits are still the usual maintenance of customers a major way, we should be properly contacted, pay more attention to, understand the hospital's inventory, to protect the patient's drug needs.in general, the essence of the pharmaceutical representative is academic promotion, technical advice, the essence of the return to regulation is the right way.the future, and the millions of medical representatives who have passed through a round of policy baptisms are bound to be reborn..